A phase Ib study of the combination regorafenib with PF-03446962 in patients with refractory metastatic colorectal cancer (REGAL-1 trial)

PURPOSE: This study aimed to evaluate the maximum tolerated dose (MTD) and recommended phase II dose (RPTD), as well as the safety and tolerability of PF-03446962, a monoclonal antibody targeting activin receptor like kinase 1 (ALK-1), in combination with regorafenib in patients with refractory meta...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Chemother Pharmacol
Main Authors: Clarke, Jeffrey Melson, Blobe, Gerard C., Strickler, John H., Uronis, Hope Elizabeth, Zafar, S. Yousuf, Morse, Michael, Dropkin, Evan, Howard, Leigh, O’Neill, Margot, Rushing, Christel N., Niedzwiecki, Donna, Watson, Hollie, Bolch, Emily, Arrowood, Christy, Liu, Yingmiao, Nixon, Andrew B., Hurwitz, Herbert I.
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Berlin Heidelberg 2019
Assuntos:
Clinical Trial Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6769092/
https://ncbi.nlm.nih.gov/pubmed/31444620
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-019-03916-0
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados